| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pharvaris N.V. | PHVS416 | Hereditary Angioedema (HAE) | Phase 3 | Trial Completed | Oral | Genetic Disorder |
| Pharvaris N.V. | Bradykinin B2 receptor - (CHAPTER-1) | Hereditary angioedema (HAE) attacks | Phase 2 | Data Released | Parenteral | Genetic Disorder |
| Phathom Pharmaceuticals Inc. | VOQUEZNA (vonoprazan) - (pHalcon-EoE-201) | Eosinophilic Esophagitis (EoE) | Phase 2 | Enrollment Initiation | Oral | Gastroenterology |
| Phathom Pharmaceuticals Inc. | VONO-103 (Vonoprazan and Lansoprazole) | Erosive esophagitis / Gastroesophageal reflux disease (GERD) | Phase 2 | Clinical Pause | Oral | Gastroenterology |
| Pieris Pharmaceuticals Inc. | QTORIN rapamycin - (SELVA) | Microcystic Lymphatic Malformations | Phase 3 | Ongoing | Topical | Genetic Disorder |
| Pieris Pharmaceuticals Inc. | Cinrebafusp alfa (PRS-343) | Gastric cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Pieris Pharmaceuticals Inc. | Elarekibep (PRS-060/AZD1402) | Asthma | Phase 2a | Trial Discontinued | Inhalation | Respiratory |
| Pliant Therapeutics Inc. | PLN-74809 - (BEACON-IPF) | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2b | Trial Discontinued | Oral | Respiratory |